Aprepitant works by targeting the neurokinin-1 (NK1) receptor, which is involved in the emetic (vomiting) response. By blocking these receptors, aprepitant prevents the action of substance P, a peptide responsible for inducing vomiting. This mechanism is particularly beneficial for patients undergoing chemotherapy, which is notorious for causing severe nausea and vomiting.
